TY - JOUR
T1 - Calcium signaling and neurodegenerative diseases
AU - Bezprozvanny, Ilya
N1 - Funding Information:
I.B. would like to thank members of his laboratory, his colleagues and collaborators for insightful discussions that helped to formulate many ideas expressed in this article and for the comments on this manuscript. I.B. also would like to sincerely apologize to many scientists working in the field of neurodegeneration whose interesting work he could not cite owing to space limitations. I.B. is a holder of Carla Cocke Francis Professorship in Alzheimer's Research and supported by the McKnight Neuroscience of Brain Disorders Award and NINDS R01 NS056224.
PY - 2009/3
Y1 - 2009/3
N2 - Neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and spinocerebellar ataxias (SCAs), present an enormous medical, social, financial and scientific problem. Recent evidence indicates that neuronal calcium (Ca2+) signaling is abnormal in many of these disorders. Similar, but less severe, changes in neuronal Ca2+ signaling occur as a result of the normal aging process. The role of aberrant neuronal Ca2+ signaling in the pathogenesis of neurodegenerative disorders is discussed here. The potential utility of Ca2+ blockers for treatment of these disorders is also highlighted. It is reasoned that Ca2+ blockers will be most beneficial clinically when used in combination with other disease-specific therapeutic approaches.
AB - Neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and spinocerebellar ataxias (SCAs), present an enormous medical, social, financial and scientific problem. Recent evidence indicates that neuronal calcium (Ca2+) signaling is abnormal in many of these disorders. Similar, but less severe, changes in neuronal Ca2+ signaling occur as a result of the normal aging process. The role of aberrant neuronal Ca2+ signaling in the pathogenesis of neurodegenerative disorders is discussed here. The potential utility of Ca2+ blockers for treatment of these disorders is also highlighted. It is reasoned that Ca2+ blockers will be most beneficial clinically when used in combination with other disease-specific therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=61849142791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61849142791&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2009.01.001
DO - 10.1016/j.molmed.2009.01.001
M3 - Article
C2 - 19230774
AN - SCOPUS:61849142791
SN - 1471-4914
VL - 15
SP - 89
EP - 100
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 3
ER -